BR112017013373A2 - tetracaine anesthetic. - Google Patents

tetracaine anesthetic.

Info

Publication number
BR112017013373A2
BR112017013373A2 BR112017013373A BR112017013373A BR112017013373A2 BR 112017013373 A2 BR112017013373 A2 BR 112017013373A2 BR 112017013373 A BR112017013373 A BR 112017013373A BR 112017013373 A BR112017013373 A BR 112017013373A BR 112017013373 A2 BR112017013373 A2 BR 112017013373A2
Authority
BR
Brazil
Prior art keywords
tetracaine
anesthetic
molars
formulations
molar
Prior art date
Application number
BR112017013373A
Other languages
Portuguese (pt)
Inventor
David Kollar Mark
Original Assignee
St Renatus Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Renatus Llc filed Critical St Renatus Llc
Publication of BR112017013373A2 publication Critical patent/BR112017013373A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M19/00—Local anaesthesia; Hypothermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/008—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised by squeezing, e.g. using a flexible bottle or a bulb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/048—Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mechanical Engineering (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a formulações anestésicas à base de tetracaína e aos métodos de uso das mesmas. a presente invenção também se refere a formulações anestésicas dentárias à base de tetracaína e a métodos para anestesiar os molares traseiros superiores da arcada dentária superior e os tecidos em torno dos molares traseiros superiores, incluindo a metade distal do primeiro molar, o segundo e o terceiro molares usando essas formulações.The present invention relates to tetracaine-based anesthetic formulations and methods of use thereof. The present invention also relates to tetracaine-based dental anesthetic formulations and methods for anesthetizing the upper posterior molars of the upper dental arch and the tissues surrounding the upper posterior molars, including the distal half of the first molar, the second and the third molar. molars using these formulations.

BR112017013373A 2014-12-23 2015-12-23 tetracaine anesthetic. BR112017013373A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096287P 2014-12-23 2014-12-23
PCT/US2015/000209 WO2016105482A1 (en) 2014-12-23 2015-12-23 Tetracaine-based anesthetic

Publications (1)

Publication Number Publication Date
BR112017013373A2 true BR112017013373A2 (en) 2018-01-02

Family

ID=55237886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013373A BR112017013373A2 (en) 2014-12-23 2015-12-23 tetracaine anesthetic.

Country Status (11)

Country Link
EP (1) EP3236941A1 (en)
JP (1) JP2017538777A (en)
KR (1) KR20170102892A (en)
CN (1) CN107249568A (en)
AU (1) AU2015371291A1 (en)
BR (1) BR112017013373A2 (en)
CA (1) CA2971156A1 (en)
EA (1) EA201791448A1 (en)
IL (1) IL253125A0 (en)
MX (1) MX2017008516A (en)
WO (1) WO2016105482A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019191200A1 (en) 2018-03-27 2019-10-03 American Genomics, Llc Method and formulation for producing anesthesia of internal aspect of eye wall by topical application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2413899T3 (en) * 2009-04-03 2021-09-20 St. Renatus, Llc Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration

Also Published As

Publication number Publication date
WO2016105482A9 (en) 2017-08-03
EA201791448A1 (en) 2017-11-30
KR20170102892A (en) 2017-09-12
JP2017538777A (en) 2017-12-28
MX2017008516A (en) 2017-09-19
AU2015371291A9 (en) 2017-08-24
AU2015371291A1 (en) 2017-08-03
IL253125A0 (en) 2017-08-31
WO2016105482A1 (en) 2016-06-30
EP3236941A1 (en) 2017-11-01
CA2971156A1 (en) 2016-06-30
CN107249568A (en) 2017-10-13

Similar Documents

Publication Publication Date Title
CY1118379T1 (en) DISEASES OF USVITIS C
CY1122786T1 (en) DOSAGE FORMS FOR Echinocandin Class Compounds
CY1120334T1 (en) Substituted 3-Halogenoyl Alamine SSAO Suspensions and Their Uses
CY1125100T1 (en) TAPENTADOL AQUEOUS PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION
CY1125068T1 (en) QUATERN-BASED ALKENE COMPOUNDS AND USE THEREOF
CY1119007T1 (en) COMPOSITIONS AND METHODS OF Pulmonary Hypertension Treatment
BR112018068748A2 (en) compound, pharmaceutical and vaccine composition, methods for inducing or promoting an immune response, for treating cancer, infectious diseases, immunological disorders and immunological diseases, and for treating or preventing a disease, and, using a compound
BR112015003188A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, COMPOUND USE, AND METHOD FOR TREATMENT OF A RORGAMMAT-MEDIATED DISEASE OR CONDITION IN A PATIENT
BR112015020453A2 (en) oral extended-release dosage forms of tofacitinib
CY1119597T1 (en) COMPOSITIONS AND METHODS FOR EXTENSION OF TRAMADOLI RESISTANCE
UY32874A (en) COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR ACTIVITY
JP1662410S (en) Patient interface
CL2015002835A1 (en) New pyridine derivatives
CY1121141T1 (en) COMPOSITION OF ORAL DISPOSABLE FILM INCLUDING ENAPRIL FOR THE TREATMENT OF HYPERTENSION IN PEDIATRIC POPULATION
JP1680688S (en) patient interface headgear
CY1118402T1 (en) USE OF SOURCE L3 AND / OR L5 AS A VACCINE OR AS A DIAGNOSIS FOR DISEASE DISEASE
IT201800001301A1 (en) Gel formulations for oral administration of drugs, particularly in dysphagia patients
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
DK3244920T3 (en) Foot and mouth disease vaccine
BR112018069682A2 (en) treatment methods for cholestatic and fibrotic diseases
CY1119522T1 (en) (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
CY1116158T1 (en) Substituted 2-oxo- and 2-thiooxy-dihydroquinoline-3-carboxamides as KCNQ2 / 3 modulators
CY1119073T1 (en) Glycosylation equivalents of HUMAN CELLULIN 1
BR112017009358A2 (en) therapeutic t-peptide specific immunotherapy for use in the treatment of brain metastasis of a hla-2 positive patient

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]